GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerpio Pharmaceuticals Inc (NAS:ARPO) » Definitions » Piotroski F-Score

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Piotroski F-Score : 0 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aerpio Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aerpio Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Aerpio Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Aerpio Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Aerpio Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerpio Pharmaceuticals Piotroski F-Score Chart

Aerpio Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Get a 7-Day Free Trial N/A 5.00 6.00 3.00 4.00

Aerpio Pharmaceuticals Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 4.00 4.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Net Income was -4.955 + -4.718 + -4.442 + -4.408 = $-18.52 Mil.
Cash Flow from Operations was -6.916 + -4.821 + -3.667 + -2.227 = $-17.63 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jun20)
to the end of this year (Jun21) was
(45.716 + 49.83 + 44.925 + 41.161 + 37.424) / 5 = $43.8112 Mil.
Total Assets at the begining of this year (Jun20) was $45.72 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $37.40 Mil.
Total Current Liabilities was $2.21 Mil.
Net Income was -4.648 + -4.446 + -3.919 + 9.276 = $-3.74 Mil.

Revenue was 0 + 0 + 0 + 15 = $15.00 Mil.
Gross Profit was 0 + 0 + 0 + 15 = $15.00 Mil.
Average Total Assets from the begining of last year (Jun19)
to the end of last year (Jun20) was
(49.6 + 45.552 + 39.937 + 35.7 + 45.716) / 5 = $43.301 Mil.
Total Assets at the begining of last year (Jun19) was $49.60 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.
Total Current Assets was $45.44 Mil.
Total Current Liabilities was $3.11 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aerpio Pharmaceuticals's current Net Income (TTM) was -18.52. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aerpio Pharmaceuticals's current Cash Flow from Operations (TTM) was -17.63. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun20)
=-18.523/45.716
=-0.40517543

ROA (Last Year)=Net Income/Total Assets (Jun19)
=-3.737/49.6
=-0.07534274

Aerpio Pharmaceuticals's return on assets of this year was -0.40517543. Aerpio Pharmaceuticals's return on assets of last year was -0.07534274. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Aerpio Pharmaceuticals's current Net Income (TTM) was -18.52. Aerpio Pharmaceuticals's current Cash Flow from Operations (TTM) was -17.63. ==> -17.63 > -18.52 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=0/43.8112
=0

Gearing (Last Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=0.01/43.301
=0.00023094

Aerpio Pharmaceuticals's gearing of this year was 0. Aerpio Pharmaceuticals's gearing of last year was 0.00023094. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun21)=Total Current Assets/Total Current Liabilities
=37.395/2.208
=16.9361413

Current Ratio (Last Year: Jun20)=Total Current Assets/Total Current Liabilities
=45.435/3.105
=14.63285024

Aerpio Pharmaceuticals's current ratio of this year was 16.9361413. Aerpio Pharmaceuticals's current ratio of last year was 14.63285024. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Aerpio Pharmaceuticals's number of shares in issue this year was 3.158. Aerpio Pharmaceuticals's number of shares in issue last year was 2.727. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15/15
=1

Aerpio Pharmaceuticals's gross margin of this year was . Aerpio Pharmaceuticals's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun20)
=0/45.716
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun19)
=15/49.6
=0.30241935

Aerpio Pharmaceuticals's asset turnover of this year was 0. Aerpio Pharmaceuticals's asset turnover of last year was 0.30241935. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aerpio Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Aerpio Pharmaceuticals  (NAS:ARPO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Aerpio Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
9987 Carver Road, Cincinnati, OH, USA, 45242
Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Pravin Dugel director C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Steven Prelack director 7 WHEELWRIGHT ROAD, MEDFIELD MA 02052
Regina Marek officer: Vice President of Finance C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242
Joseph H. Gardner director, officer: President C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Kevin G. Peters officer: See Remarks C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242
Muneer A Satter director, 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Chau Quang Khuong director, 10 percent owner C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael W Rogers officer: See Remarks C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Stephen J Hoffman director, officer: Chief Executive Officer C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056